BioCentury
ARTICLE | Emerging Company Profile

RNA ligands take SHAPE

How Ribometrix is identifying small molecules that bind RNA targets

April 13, 2017 5:32 PM UTC

Ribometrix Inc. is creating small molecule therapeutics that bind RNA with a dual platform technology that allows it to map the conformational structure of RNA molecules, identify druggable pockets and screen for ligands.

The company was founded in 2015 with an exclusive license to a pair of high throughput platforms, SHAPE-MaP (Selective 2’-Hydroxyl Acylation analyzed by Primer Extension-Mutational Profiling) and RING-MaP (RNA INteraction Groups by Mutational Profiling), developed in the lab of co-founder and interim CEO Kevin Weeks, who is also a professor of chemistry at the University of North Carolina at Chapel Hill. ...

BCIQ Company Profiles

Ribometrix Inc.